|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
CA224-047 |
Bösartiges Melanom der Haut, nicht näher bezeichnet
[C43.9]
|
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Z:339
|
 |
 |
|
|
CABL001A2301 |
Chronische myeloische Leukämie [CML], BCR/ABL-positiv
[C92.1]
|
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase Inhibitors
|
 |
|
|
|
Cabozantinib |
Bösartige Neubildung der Prostata
[C61]
|
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
|
|
|
|
|
CAIN457A2303 |
Psoriasis, nicht näher bezeichnet
[L40.9]
|
A randomized, double-blind, placebo controlled, multicenter study of subcutaneous AIN457 to demonstrate efficacy at Week 12 compared to placebo and etanercept and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis.
|
|
|
|
|
CAIN457ADE01T (Secukinomab) |
Pyoderma gangraenosum
[L88]
|
Pilotstudie zum Einsatz von anti-IL-17 (Secukinumab) bei der Behandlung von Pyoderma gangraenosum CAIN457ADE01T
|
|
|
|
|
CAIN457FDE03 ASTRUM |
Spondylitis ankylosans
[M45.0]
|
A randomized, double-blind, placebo-corntrolled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ankylosing Spondylitis (ASTRUM)
|
|
|
|
CAMN107DDE05 |
GIST
[C15-C19]
|
An open-label, multi-center study to evaluate the efficiency of nilotinib in adult patients with GIST tumors resistant to imatinib and sunitinib
|
 |
|
|
|
CAMN107DDE06 |
GIST
[C15-C19]
|
An open label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable GIST in first line treatment
|
|
|
|
|
CAMN107G2301 |
GIST
[C15-C19]
|
A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib vs. imatinib in adult patients with unresectable or metastatic GIST
|
 |
|
|
|
CAO/ARO/AIO-04 |
Bösartige Neubildung am Rektosigmoid, Übergang
[C19]
|
Prospektiv randomisierte, multizentrische Studie der Phase III: Präoperative Radio-/Chemotherapie und adjuvante Chemotherapie mit 5-Fluorouracil plus Oxaliplatin im Vergleich zu einer präoperativen Radio-/Chemotherapie und adjuvanten Chemotherapie mit 5-Fluorouracil beim lokal fortgeschrittenen Rektumkarzinom im UICC-Stadium II und III
|
|
|
|
|
CAO/ARO/AIO-04 |
kolorektales Karzinom
[C19]
|
Prospektiv randomisierte, multizentrische Studie der Phase III: Präoperative Radio-/Chemotherapie und adjuvante Chemotherapie mit Capecitabin plus Oxaliplatin im Vergleich zu einer präoperativen Radio-/Chemotherapie und adjuvanten Chemotherapie mit 5-Fluorouracil beim lokal fortgeschrittenen Rektumkarzinom im UICC-Stadium II und III
|
|
|
|
|
CAPRELSAT |
Bösartige Neubildung der Schilddrüse
[C73]
|
European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer
|
|
|
|
|
CARIN-Studie |
Bösartige Neubildung der Brustdrüse [Mamma]
[C50.-]
|
Verbesserung der Wirksamkeit eines Therapieregime aus Capecitabin und Bevacizumab bei Patientinnen mit metastasiertem oder inoperablem HER2/neu negativem Mammakarzinom durch Zusatz von Vinorelbin.
|
|
|
|
|
CASSINI |
Hämostaseologie
[-]
|
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
|
|
|
|
|
Catalyst |
Sonstiges
[-]
|
Prospektive Beobachtungsstudie bei der Positionierung von Patienten während der Strahlentherapie durch die Anwendung eines optischen Oberflächenscanners (Catalyst™-System)
|
|
|
|
|
CBYL719A2201 |
Brustdrüse, nicht näher bezeichnet
[C50.9]
|
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Letrozole with or without BYL719 or Buparlisib for the Neoadjuvant Treatment of Postmenopausal Women with Hormon Receptor-Positive, HER2-negative Breast Cancer
|
|
|
|
|
CC- 5013-PASS-001 |
Multiples Myelom
[C90.0-]
|
A non-interventional observational post authorisation safety study of subjects treated with lenalidomide
|
|
|
|
|
CC-486-AML-001 |
Akute myeloblastische Leukämie [AML]
[C92.0]
|
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to compare efficacy and safety of Oral Azacitidine plus best supportive care versus best supportive care as Maintenance Therapy in subjects with Acute Myeloid Leukemia in complete remission
|
|
|
|
|
CC-486-MDS-006 |
Myelodysplastische Syndrome
[D46.-]
|
A PHASE 2, INTERNATIONAL, MULTICENTER,
RANDOMIZED, OPEN-LABEL, PARALLEL GROUP
STUDY TO EVALUATE THE EFFICACY AND SAFETY
OF CC-486 (ORAL AZACITIDINE) ALONE AND IN
COMBINATION WITH DURVALUMAB (MEDI4736) IN
SUBJECTS WITH MYELODYSPLASTIC SYNDROMES
WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE
TO TREATMENT WITH AZACITIDINE FOR
INJECTION OR DECITABINE
|
|
|
|
|
CC-5013-MDS-010 (PASS) |
Myelodysplastisches Syndrom mit isolierter del(5q)-Chromosomenanomalie
[D46.6]
|
A prospective non-interventional post-authorization safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndrome (MDS) and isolated del(5q)
|
|
|
|
|
CC-5013-MM-019 |
Multiples Myelom
[C90.0-]
|
CC-5013-MM-019 A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAMFOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITHMULTIPLE MYELOMA
|
|
|
|
|
CC-5013-MM-020 |
Multiples Myelom
[C90.0-]
|
A Phase III, Randomized,Open-Label, 3-Arm Study to determine theefficacy and safety of lenalidomide (Revlimid) plus low-dose Dexamethasone when given until progressive disease or for safety of lenalidomide (Revlimid) plus low-dose Dexamethasone when given until progressive disease or for 18 four-week cycles versus the combination of Melphalan, Prednisone, and Thalidomide given for 12 six-week cycles in patients with previously untreated multiple myeloma who are either 65 years of age or older or not candidates for stem cell transplantation.
|
|
|
|
|
CC-5013-PC-002 |
Prostatakarzinom
[C61]
|
A phase 3 study to evaluate the efficacy and safety of Docetaxel and Prednisone with or without Lenalidomide in subjects with castrate-resistant Prostate cancer
|
|
|
|
|
CDR0000370860 |
Bösartige Neubildung der Cervix uteri
[C53.-]
|
An international multi center phase III study of chemoradiotherapy versus chemoradiotherapy plus hyperthermia for locally advanced cervical cancer
|
|
|
|
|
CELESTIAL XL184-309 |
Leberkrankheit, nicht näher bezeichnet
[K76.9]
|
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
|
|
|
